AP
$21.75
+0.24
(+1.12%)
As of Oct 5, 2026, 4:19 PM EDT
Price history
Apnimed (APMD) is trading up at $21.75 (+1.12%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Apnimed revenue & net income history
RevenueNet income
| Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q1 FY26†Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $3.13M | $17.1M | $84.8M | $12.1M |
| Growth (year over year) | — | — | +2608.8% | −29.4% |
| Operating income | −$27.1M | −$5.94M | $68.0M | −$11.7M |
| Operating margin | −865.9% | −34.7% | 80.2% | −96.9% |
| Net income | −$28.6M | −$69.5M | $67.7M | $125.9M |
| Net margin | −914.9% | −406.0% | 79.8% | 1042.5% |
| Balance sheet | ||||
| Cash and equivalents | — | — | — | $172.8M |
| Total assets | — | — | — | $195.5M |
| Total liabilities | — | — | — | $125.7M |
| Long-term debt | — | — | — | $40.3M |
| Shareholders' equity | −$276.5M | −$345.0M | −$304.1M | −$176.2M |
From Apnimed's 10-Q filings with the SEC. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Apnimed
- Headquarters
- Cambridge, Massachusetts From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with APMD
- ANTX AN2 Therapeutics
- ANVS Annovis Bio
- AORT Artivion Inc
- APGE Apogee Therapeutics Inc
- APRE Aprea Therapeutics
- APUS Apimeds Pharmaceuticals US
- AQST Aquestive Therapeutics Inc
- ARAY Accuray Inc